Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
10 Feb 2021
10 Feb 2021
Historique:
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
18
2
2021
Statut:
epublish
Résumé
The biological determinants of the wide spectrum of COVID-19 clinical manifestations are not fully understood. Here, over 1400 plasma proteins and 2600 single-cell immune features comprising cell phenotype, basal signaling activity, and signaling responses to inflammatory ligands were assessed in peripheral blood from patients with mild, moderate, and severe COVID-19, at the time of diagnosis. Using an integrated computational approach to analyze the combined plasma and single-cell proteomic data, we identified and independently validated a multivariate model classifying COVID-19 severity (multi-class AUCtraining = 0.799, p-value = 4.2e-6; multi-class AUCvalidation = 0.773, p-value = 7.7e-6). Features of this high-dimensional model recapitulated recent COVID-19 related observations of immune perturbations, and revealed novel biological signatures of severity, including the mobilization of elements of the renin-angiotensin system and primary hemostasis, as well as dysregulation of JAK/STAT, MAPK/mTOR, and NF-κB immune signaling networks. These results provide a set of early determinants of COVID-19 severity that may point to therapeutic targets for the prevention of COVID-19 progression.
Identifiants
pubmed: 33594362
doi: 10.1101/2021.02.09.430269
pmc: PMC7885914
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIGMS NIH HHS
ID : R35 GM137936
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM130900
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI146268
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM138353
Pays : United States
Organisme : Doris Duke Charitable Foundation
ID : 2018100
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Sci Signal. 2018 Sep 25;11(549):
pubmed: 30254055
J Hosp Med. 2021 Feb;16(2):90-92
pubmed: 33147129
Allergy Asthma Clin Immunol. 2006 Sep 15;2(3):98-108
pubmed: 20525154
Nat Med. 2018 May;24(4):474-483
pubmed: 29505032
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Rheumatol Int. 2012 May;32(5):1335-42
pubmed: 21298269
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Nat Immunol. 2016 Feb;17(2):122-31
pubmed: 26784265
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Lancet Rheumatol. 2020 Dec;2(12):e779-e790
pubmed: 33073244
Cell Rep Med. 2020 Aug 25;1(5):100078
pubmed: 32838342
Sci Transl Med. 2014 Sep 24;6(255):255ra131
pubmed: 25253674
Lancet. 2020 Oct 3;396(10256):968-976
pubmed: 33010842
Lancet Respir Med. 2020 Oct;8(10):946-949
pubmed: 32444269
Nat Mach Intell. 2020 Oct;2(10):619-628
pubmed: 33294774
Trends Immunol. 2019 Jul;40(7):565-583
pubmed: 31160207
Nat Rev Immunol. 2010 Feb;10(2):103-10
pubmed: 20081870
Curr Top Microbiol Immunol. 2014;377:1-21
pubmed: 24671264
Front Immunol. 2020 Jul 10;11:1708
pubmed: 32754163
Cell Rep Med. 2020 Dec 26;2(1):100166
pubmed: 33521697
Sci Immunol. 2021 Jan 21;6(55):
pubmed: 33478949
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Bioinformatics. 2019 Jan 1;35(1):95-103
pubmed: 30561547
Front Immunol. 2020 Aug 26;11:2037
pubmed: 32983152
Nat Protoc. 2015 Feb;10(2):316-33
pubmed: 25612231
Nat Commun. 2020 Jul 27;11(1):3737
pubmed: 32719355
J Crit Care. 2018 Feb;43:48-53
pubmed: 28843664
Nat Nanotechnol. 2020 Aug;15(8):630-645
pubmed: 32661375
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Cytometry A. 2013 May;83(5):483-94
pubmed: 23512433
PLoS One. 2019 Dec 5;14(12):e0225051
pubmed: 31805065
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Cell. 2020 Dec 10;183(6):1479-1495.e20
pubmed: 33171100
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
J Allergy Clin Immunol. 2014 Feb;133(2):500-10
pubmed: 24636474
J Leukoc Biol. 2020 May;107(5):809-818
pubmed: 32170882
Sci Immunol. 2020 Jul 15;5(49):
pubmed: 32669287
Brain. 2019 Apr 1;142(4):978-991
pubmed: 30860258
Sci Rep. 2020 Nov 10;10(1):19395
pubmed: 33173052
Blood Adv. 2020 Nov 10;4(21):5378-5388
pubmed: 33141886
PLoS One. 2011;6(10):e26247
pubmed: 22022579
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Respir Res. 2018 Feb 3;19(1):23
pubmed: 29394894
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
Nat Rev Immunol. 2020 Jul;20(7):395-396
pubmed: 32488201
Blood. 2017 Feb 9;129(6):759-770
pubmed: 28011673
Lancet Respir Med. 2020 Dec 17;:
pubmed: 33341155
Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1217-29
pubmed: 9351625
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32687484
Crit Care. 2020 Jul 13;24(1):422
pubmed: 32660650
J Clin Invest. 2020 Nov 2;130(11):5800-5816
pubmed: 33044226
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Mol Syst Biol. 2018 Jun 20;14(6):e8124
pubmed: 29925568
Blood. 2007 Feb 1;109(3):1026-33
pubmed: 17047157
Sci Immunol. 2020 Sep 28;5(51):
pubmed: 32989174
Cell Syst. 2021 Jan 20;12(1):23-40.e7
pubmed: 33096026
mSphere. 2020 Jun 24;5(3):
pubmed: 32581077